Zhejiang Cancer Hospital
🇨🇳China
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06562920
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
Phase 2
Recruiting
- Conditions
- Bone MetastasesTriple-negative Breast Cancer
- Interventions
- Other: Rankl inhibitor
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06538896
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery
Not Applicable
Recruiting
- Conditions
- EsketamineAnxiety State
- Interventions
- Drug: normal saline
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT06530706
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Phase 2
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Radiation: Neoadjuvant chemoradiotherapy followed by immunotherapyDrug: Neoadjuvant chemoimmunotherapy
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT06509568
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC
Phase 2
Not yet recruiting
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT06478043
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Combined Screening for Gastrointestinal Tumors
Recruiting
- Conditions
- Gastrointestinal Tumors
- Interventions
- Diagnostic Test: questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 200000
- Registration Number
- NCT06478030
- Locations
- 🇨🇳
Yongkang City, Jinhua, Zhejiang, China
🇨🇳Fenghua District, Ningbo, Zhejiang, China
Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06437678
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06422858
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy
Phase 2
Not yet recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 138
- Registration Number
- NCT06419140
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- SintilimabChemoradiotherapyElderly PatientsEsophageal CancerImmunotherapy
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 191
- Registration Number
- NCT06413342
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath